MacroGenics, Inc. (NASDAQ:MGNX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President
MacroGenics (MGNX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to earnings of $0.21 per share a year ago.
ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based ther
MacroGenics' stock has increased by 230% since September due to favorable macroeconomics and interest in antibody-drug conjugates. The company is testing vobramitamab duocarmazine for the treatment of
ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibod
MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the
Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biotech
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-b
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital
MacroGenics, Inc. (MGNX) Q3 2023 Earnings Call Transcript
ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based ther
ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therap
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therap
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE